Chr. Hansen plans to strengthen biological solutions amid 7% organic growth in 2020/2021
date:Oct 15, 2021
and was impacted positively from acquisitions and negatively by 7% due to currency effects. Revenue from acquisitions amounted to 105 million (US$122 million).

COVIDs ripple effect
The prolonged impact from the COVID-19 pandemic increased the complexity of transitioning Chr. Hansen to a fully-focused bioscience company, outlines Graber.

In July, Chr. Hansen published its Q3 2020/21 financial results, reporting an overall 8% organic growth, but 0% organic growth in its Health and Nutrition se
2/10 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/25 18:18